North America Transcatheter Aortic Valve Replacement (TAVR) Market Report

North America Transcatheter Aortic Valve Replacement (TAVR) Market Size

The transcatheter aortic valve replacement (TAVR) market in North America was valued at USD 1.14 billion in 2025. The North American market size is anticipated to grow at a CAGR of 16.8% from 2026 to 2034 and be worth USD 4.61 billion by 2035 from USD 1.13 billion in 2026.

Most doctors have accepted the TAVR procedure due to its positive results recorded over the past several years. Transcatheter aortic valve replacement is indicated in several disorders such as aortic valve stenosis, arrhythmias, regurgitation, aortic valve, and sternotomy.

MARKET DRIVERS

The rising prevalence of cardiovascular diseases, along with increasing technological development, is driving the North American TAVR market. Aortic stenosis is one of the most common types of aortic valve problems seen in Americans, with over 1.29 million Americans, mainly over the age of 65, having calcified aortic valves. According to data from the National Health and Nutrition Examination Survey report, approximately 6.28 million U.S. adults aged ≥20 years suffered from heart failure between 2014 and 2017, compared with about 5.8 million between 2010 and 2013. More than 5.8 million Americans suffer from heart failure, and there are approximately 916,000 new patients diagnosed with the disease each year. Since the aortic valve catheter replacement (TAVR) procedure was approved in 2011, more than 276,500 patients have undergone the TAVR procedure in the United States. All the statistics mentioned above are estimated to increase over the years, which will increase the demand for TAVR during the forecast period.

MARKET RESTRAINTS

The preference for TAVR is dependent on the clinical success of low-risk patients. While this is a good alternative but there is less data on the longer-term effects post-procedure. Many surgeons are still limiting the number of patients undergoing the procedure. Selected patients are monitored for the long-term durability of the valve over ten years to watch out for any complications. Hence, the main limiting factor for the slow growth of the market is the lack of clinical data on long-term sustainability.

REPORT COVERAGE

REGIONAL ANALYSIS

The United States dominated the North American transcatheter aortic valve replacement (TAVR) market in 2025, followed by Canada. The regional market in the U.S. can be attributed to the increasing incidence of cardiovascular disease disorders in the region. Cardiovascular disease (CVD) is the leading cause of death in the United States, recorded over 845,000 deaths. Between 2014 and 2017, over 123 million American adults suffered from cardiovascular disease. In addition, according to the American Heart Association, an estimated 117 million or 46.5% of American adults suffer from hypertension. According to the American College of Cardiology Journal, over 25,000 transcatheter valve replacement procedures were performed in the United States in 2016. That number is expected to reach 150,000 procedures by 2027. These factors drive the market in the United States during the projected period.

Canada is also anticipated to grow at a healthy CAGR over the forecast period. The growth can be due to technologically advanced products, favorable reimbursement policies, and a large senior population. About 1 in 12 Canadian adults, or over 2.55 million above 20 years of age, are suffering from heart disease and receiving treatment for it. Every hour, about 12 Canadian adults aged 20 and over die from diagnosed heart disease. Additionally, increasing mergers and acquisitions among the major players and favorable reimbursement policies are some of the factors boosting the growth of the studied market in Canada.

KEY MARKET PLAYERS

Companies playing a dominant role in the North American transcatheter aortic valve replacement market include

• Edwards Lifesciences Corporation (U.S.)
• Medtronic, Inc. (Ireland)
• Boston Scientific Corporation (U.S.)
• Abbott Laboratories (U.S.)
• St. Jude Medical Inc. (U.S.)
• JenaValve Technology, Inc. (Germany)
• Symetis SA (Switzerland)
• Direct Flow Medical, Inc. (U.S.)
• Sorin Group (Italy)
• Meril Life Sciences India Pvt Ltd (India)
• Braile Biomedica (Brazil)

MARKET SEGMENTATION

This research report on the North American transcatheter aortic valve replacement (TAVR) market is segmented and sub-segmented into the following categories

By Surgery Method

• Transfemoral Implantation
• Transapical Implantation
• Transaortic Implantation
• Transvaal Implantation

By Valve Material

• Nitinol
• Stainless Steel
• Cobalt-Chromium              

By Valve Size

• 14mm to 18 mm
• 18mm to 22 mm
• 22mm to 29mm                    

By Valve Leaflets Material

• Bovine Heart Tissue
• Cow Heart Tissue
• Other Valve Leaflets Material                       

By End Users

• Hospitals
• Ambulatory Surgical Centres
• Cardiac Catheterization Laboratories     

By Country

• The United States
• Canada
• Rest of North America